Braskem Reports Steep EBITDA Decline, 14.74x Leverage Amid Challenging Market
BAK sits 55% above its 52-week low of $2.32 on elevated volume (3.5× avg).
Summary
Braskem presented its 4Q25 and full-year 2025 earnings, revealing a significant drop in recurring EBITDA, negative operating cash flow, and an alarming corporate leverage ratio of 14.74x, reflecting a prolonged petrochemical downturn.
Key Events · Earnings and Guidance · BAK
-
Significant Financial Deterioration
Recurring EBITDA for 2025 fell by 49% to US$557 million, with 4Q25 EBITDA at US$109 million, down 27% quarter-over-quarter.
-
Alarming Corporate Leverage
Corporate leverage reached 14.74x at the end of 2025, a substantial increase from 7.42x in 2024, highlighting severe financial distress.
-
Negative Cash Flow
The company reported negative operating cash generation of approximately US$(246) million for the full year 2025, indicating cash consumption.
-
Challenging Market Conditions
The global petrochemical market faced weak demand, excess supply, and pressure on spreads, impacting all operating segments (Brazil, USA & Europe, Mexico).
Analysis · BAK · Industrial Applications And Services
This earnings presentation provides critical details following earlier reports of a substantial net loss for 2025. The company's recurring EBITDA plummeted by 49% year-over-year, and it experienced negative operating cash generation for the full year. Most notably, corporate leverage surged to an extremely high 14.74x, indicating severe financial strain and heightened risk. While Braskem outlined a resilience program and strategic priorities for 2026, the current financial health, exacerbated by a volatile global petrochemical market and geopolitical tensions, presents significant challenges to business continuity and value recovery. Investors should monitor the company's ability to reorganize its capital structure and improve cash flow.
At the time of this filing, BAK was trading at $3.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $2.32 to $5.30. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.